Detalles de la búsqueda
1.
Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
Mult Scler
; 22(7): 944-54, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26447066
2.
Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study.
Mult Scler
; 20(2): 253-7, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24150778
3.
Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study.
Mult Scler
; 20(2): 243-52, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24150779
4.
Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study.
Health Qual Life Outcomes
; 10: 155, 2012 Dec 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-23270428
5.
An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Expert Opin Pharmacother
; 20(4): 473-481, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30489166
6.
Evaluating Prognostic Factors for Liver Transplantation Among United States Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis Using National Registry Data.
Prog Transplant
; 29(3): 213-219, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31167608
7.
Patient Perspective on Acute Intermittent Porphyria with Frequent Attacks: A Disease with Intermittent and Chronic Manifestations.
Patient
; 11(5): 527-537, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29915990
8.
Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis.
Patient Prefer Adherence
; 11: 1035-1048, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28670113
9.
Development of the multiple sclerosis (MS) early mobility impairment questionnaire (EMIQ).
J Neurol
; 263(10): 1969-83, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27393117
10.
Response to the letter to the editor on "an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy".
Expert Opin Pharmacother
; 20(12): 1529-1530, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31124741
11.
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
Curr Med Res Opin
; 30(4): 613-27, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24195574
12.
Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.
Adv Ther
; 28(1): 51-61, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21153000
13.
Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis.
Adv Ther
; 28(9): 761-75, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21870169
14.
Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis.
Patient Prefer Adherence
; 5: 73-84, 2011 Jan 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-21423591
15.
Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
J Med Econ
; 14(5): 617-27, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21777161
16.
Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional survey.
Patient
; 2(2): 105-12, 2009 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22273086
Resultados
1 -
16
de 16
1
Próxima >
>>